TransMedics Group, Inc.TMDXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank91
5Y CAGR+30.4%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+30.4%/yr
Long-term compound
Percentile
P91
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 35.66% |
| Q3 2025 | -4.23% |
| Q2 2025 | -7.14% |
| Q1 2025 | 4.23% |
| Q4 2024 | 15.41% |
| Q3 2024 | 2.94% |
| Q2 2024 | 21.78% |
| Q1 2024 | 5.75% |
| Q4 2023 | -71.94% |
| Q3 2023 | 362.48% |
| Q2 2023 | 41.22% |
| Q1 2023 | 2.00% |
| Q4 2022 | -15.45% |
| Q3 2022 | 1.40% |
| Q2 2022 | -10.88% |
| Q1 2022 | 19.32% |
| Q4 2021 | 22.29% |
| Q3 2021 | -17.98% |
| Q2 2021 | 38.90% |
| Q1 2021 | -0.35% |
| Q4 2020 | 9.46% |
| Q3 2020 | 6.46% |
| Q2 2020 | -37.30% |
| Q1 2020 | -0.59% |
| Q4 2019 | 26.79% |
| Q3 2019 | 3.18% |
| Q2 2019 | 23.31% |
| Q1 2019 | 11.36% |
| Q4 2018 | 6.54% |
| Q3 2018 | -4.69% |
| Q2 2018 | -0.92% |
| Q1 2018 | 1.85% |
| Q4 2017 | 0.00% |
| Q3 2017 | -18.86% |
| Q3 2017 | 2.86% |
| Q2 2017 | 0.00% |